CTOs on the Move

Achaogen

www.achaogen.com

 
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are anchored in our work by our key values of integrity, accountability, transparency, scientific rigor and drive. We pride ourselves in creating a work community that is patient-centric, scientifically driven, supportive, and collaborative, and that encourages the diversity of thought leading to great innovation. We are always excited to add people to our dynamic team who thrive in our community and who are driven and motivated to transform the lives of patients.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.achaogen.com
  • 7000 & 6000 Shoreline Court #371
    South San Francisco, CA USA 94080
  • Phone: 650.800.3636

Executives

Name Title Contact Details

Funding

Achaogen raised $116.61M on 06/14/2016

Similar Companies

Mind Medicine

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Chelsea Therapeutics

Chelsea Therapeutics is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

13Therapeutics Inc

13Therapeutics Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CNS Therapeutics

CNS Therapeutics is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Principia Biopharma

Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.